The EAE Score is a standardized. clinical scoring system that assesses the disease progression in this rodent model. It typically uses a 5 point scale. An example is:

There are several variations on the EAE score, and we would be happy to discuss what may be most suitable for your study.

The dosing paradigm can be:
(1) Prophylactic (starting before or at the time of immunization)
(2) Therapeutic/interventional
      (a) Starting when the first mice show symptoms
      (b) Starting from the first signs of symptoms in each mouse
      (c) Starting a fixed time after immunization or symptom onset in each mouse

Our team can discuss the best dosing paradigm for your study.

Yes. The existence of well-established positive controls is an advantage of the EAE animal models.

The MOG_1-125 induced model is thought to have some dependence on B cells, which may be useful for evaluating B cell-targeted therapies.

In active EAE, the disease is induced in mice via immunization with myelin-derived antigens, such as MOG, PLP, or MBP. MOG_35-55-induced EAE is commonly used to induce EAE in C57BL/6 mice, making is a well-established and widely employed rodent model for studying autoimmune demyelinating diseases.

In passive EAE (also known as adoptive transfer), the disease is induced by first generating encephalitogenic CD4+ T cells that are specific for myelin-derived antigens in immunized (donor) mice, then activated these cells in culture, and finally injecting them into recipient mice. This approach is useful when therapies target specific T cell populations.

Yes. We can generate these animal models and our EAE model scientists would be happy to discuss further with you.

Definitely. Plasma and/or CSF neurofilament light levels are excellent measures of axonal damage in this mouse model of multiple sclerosis.